Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery

ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II

(2014) M. Schnurr et al.   JOURNAL OF IMMUNOLOGY

A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design

(2009) L. M. Ebert et al.   CANCER RESEARCH

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant

(2009) Eugene Maraskovsky et al.   IMMUNOLOGY AND CELL BIOLOGY

Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients

(2008) Ashley J. Knights et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells

(2008) Neil C. Robson et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cancer Immunotherapy by Dendritic Cells

(2008) Cornelis J.M. Melief   IMMUNITY

Demystifying the development of dendritic cell subtypes, a little

(2008) Shalin H Naik   IMMUNOLOGY AND CELL BIOLOGY